F-4633 Fingolimod, Hydrochloride Salt, >99%

Synonyms : [FTY-720A] [FTY720]

Related Terms : [Gilenia] [Gilenya] [Gilena]

  • Size
  • US $
  • £
  • ¥
  • 100 mg
  • 48
  • 45
  • 38
  • 5,500
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 87
  • 81
  • 69
  • 10,000
  • Add to Cart Qty:
  • In stock
  • 300 mg
  • 122
  • 114
  • 96
  • 14,000
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 174
  • 163
  • 138
  • 19,900
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 232
  • 218
  • 184
  • 26,500
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 416
  • 391
  • 330
  • 47,600
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 850
  • 800
  • 674
  • 97,300
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 343.93
  • C19H33NO2•HCl
  • [162359-56-0]
  • M.I. 14: 4083

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 100 mg/mL; very poorly soluble in water. Up to 25 µL of a solution of 13.8 mg/mL (40 mM) fingolimod-HCl in 100% DMSO can be diluted into 5 mL of plain water without precipitation, giving a final concent. Disposal: A.

  • Fingolimod (FTY720), a sphingosine 1-phosphate (S1P) analog, is a novel immunosuppressant drug that induces lymphopenia by preventing emergence of lymphocytes from lymph nodes. Fingolimod is a sphingosine-1-phosphate receptor 1 modulator and is in phase III clinical trials for relapsing-remitting multiple sclerosis. Chiba, K., et al. "Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus." Cell Mol. Immunol. 3: 11-19 (2006). Dev, K.K., et al. "Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis." Pharmacol. Ther. 117: 77-93 (2008).
  • Suppresses allotransplant rejections and autoimmune disorders in different animal models. Kunzendorf, U., et al. "FTY720—the first compound of a new promising class of immunosuppressive drugs." Nephrol. Dial. Transplant. 19: 1677-1681 (2004).
  • Fingolimod appears to promote the survival of human and animal allografts by sequestering T lymphocytes within peripheral lymphoid tissue. Evidence for this mechanism of sequestration includes: (1) fingolimod drives T lymphocytes into peripheral lymph nodes in a chemokine dependent manner; (2) fingolimod downregulates sphingosine 1-phosphate receptors (S1PRs) on the T lymphocyte surface, preventing it from migrating along a S1P gradient; and (3) fingolimod blocks stromal gates on the abluminal side of the lymphatic endothelium. Yopp, A.C., et al. "Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants." Clin. Transplant. 20: 788-795 (2006).
  • Fingolimod, as the hydrochloride salt, is the active ingredient in the drug sold under the trade names Gilenya® and Gilenia® by Novartis AG. This drug is currently approved in at least one country for use in patients with relapsing forms of multiple sclerosis. NOTE: THE FINGOLIMOD, HYDROCHLORIDE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GILENYA® nor GILENIA® AND IS NOT FOR HUMAN USE. Gilenya® is a registered trademark of Novartis AG. LC Laboratories is not affiliated with Novartis AG, and the fingolimod hydrochloride research compound sold by LC Laboratories is not manufactured by Novartis AG.
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
  • Please see also our other standard immunosuppressant products: A-1040 Ascomycin C-6000 Cyclosporin A E-4040 Everolimus F-4900 FK-506 P-6040 Pimecrolimus R-5000 Rapamycin T-8040 Temsirolimus T-1377 Tofacitinib, Free Base Z-9040 Zotarolimus
110